Organovo Holdings, Inc. (ONVO) News
Filter ONVO News Items
ONVO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ONVO News Highlights
- For ONVO, its 30 day story count is now at 3.
- Over the past 23 days, the trend for ONVO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LINK and NOV are the most mentioned tickers in articles about ONVO.
Latest ONVO News From Around the Web
Below are the latest news stories about ORGANOVO HOLDINGS INC that investors may wish to consider to help them evaluate ONVO as an investment opportunity.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsSAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024. The |
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today ann |
OVNO Continues Developing Breakthrough TreatmentsBy Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained |
Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)Organovo Holdings ( NASDAQ:ONVO ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.99m (loss widened by... |
Organovo Highlights FXR314 Combination Therapy Potential and PlanSAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the dat |
ONVO: A Company With Great Technology to Impact Health CareBy Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology, the focus of which is currently around the intestinal area and inflammatory |
Organovo to Participate in the H.C. Wainwright Global Investment ConferenceSAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co |
Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapUnpacking the Financial Health of Organovo Holdings Inc (ONVO) to Determine Its Investment Viability |
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataSAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral |
Net Asset Value(s)LONDON, July 12, 2023-- FundsDate |